NCT03632759View on ClinicalTrials.gov

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 15, 2018

Primary Completion Date

November 9, 2021

Study Completion Date

November 9, 2021

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Liraglutide

Participants will receive subcutaneous (SC) liraglutide for 8 weeks

DRUG

Golimumab

Participants will receive subcutaneous (SC) golimumab for 8 weeks

Trial Locations (2)

83404

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls

98101

Benaroya Research Institute, Seattle

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Carla Greenbaum, MD

OTHER